APH-1104

APH-1104 is an experimental small-molecule analog of bryostatin 1 being developed by Aphios/Amylon as a highly potent modulator of alpha (α)-secretase for the treatment of Alzheimer’s disease. It acts as a protein kinase C (PKC) modulator that preferentially stimulates the non-amyloidogenic α-secretase pathway, enhancing soluble amyloid precursor protein (sAPP) generation and thereby reducing pathogenic amyloid-β formation while exerting neuroprotective effects.[3][8][9][10] Preclinical studies indicate that APH-1104 is several orders of magnitude more potent than typical α-secretase modulators and more potent than earlier Aphios candidates, with strong activity in α-secretase assays and supporting data from oral formulations of related, less potent analogs that rapidly reversed cognitive deficits in triple-transgenic Alzheimer’s disease mouse models.[3][8] APH-1104 remains in development for Alzheimer’s disease and is part of a broader Aphios program exploring bryostatin analogs as disease-modifying therapies targeting synaptic and cognitive impairment.[3][9][10]

Other names

bryostatin 1 analogbryostatin1 analogbryostatin-1 analogalpha-secretase modulator